Quiero saber acerca de...

Federal Register / Vol. 86, No. 31 / Thursday, February 18, 2021 / Notices
10081

EARLY TERMINATIONS GRANTEDContinued 12/01/2020 12:00:00 a.m.,12/31/2020 12:00:00 a.m.
12/28/2020
20210205
20210689
20210690
20210691

G
G G
G

Caesars Entertainment, Inc.; William Hill PLC; Caesars Entertainment, Inc.
Biogen Inc.; Sage Therapeutics, Inc; Biogen Inc.
Thoma Bravo Fund XIIIA, L.P.; Venafi, Inc; Thoma Bravo Fund XIIIA, L.P.
Nasdaq, Inc.; Verafin Holdings, Inc.; Nasdaq. Inc.
12/31/2020

20210651
20210652
20210653

G
G G

Stephen Griggs; AdaptHealth Corp.; Stephen Griggs.
SkyKnight Aero Holdings, LLC; AdaptHealth Corp.; SkyKnight Aero Holdings, LLC.
Peloton Equity AeroCare SPV I, L.P.; AdaptHealth Corp.; Peloton Equity AeroCare SPV I, L.P.

1811, Morgantown, West Virginia 26505, Telephone 304 2855879.
The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

FOR FURTHER INFORMATION CONTACT:

Theresa Kingsberry 2023263100, Program Support Specialist, Federal Trade Commission Premerger Notification Office, Bureau of Competition, Room CC5301, Washington, DC 20024.
By direction of the Commission.
April J. Tabor, Secretary.
FR Doc. 202103183 Filed 21721; 8:45 am BILLING CODE P

Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and Prevention
FR Doc. 202103231 Filed 21721; 8:45 am BILLING CODE 416318P

jbell on DSKJLSW7X2PROD with NOTICES

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel SEPFunding Opportunity Announcement FOA, RFA OH21003, Extension of the World Trade Center Health Registry U50; Amended Notice of Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES

VerDate Sep<11>2014

18:18 Feb 17, 2021

Jkt 253001

National Center for Advancing Translational Sciences; Notice of Closed Meeting Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center for Advancing Translational Sciences Special Emphasis Panel; CTSA Revision Award.
Date: March 9, 2021.
Time: 12:00 p.m. to 6:00 p.m.

PO 00000

Frm 00048

Fmt 4703

Sfmt 4703

Dated: February 11, 2021.
David W. Freeman, Program Analyst, Office of Federal Advisory Committee Policy.
FR Doc. 202103190 Filed 21721; 8:45 am BILLING CODE 414001P

National Institutes of Health
Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel SEPFunding Opportunity Announcement FOA, RFA OH21003, Extension of the World Trade Center Health Registry U50, April 13, 2021; 9:00 a.m.6:00
p.m., EDT in the original FRN.
The virtual meeting was published in the Federal Register on Monday, January 11, 2021, Volume 86, Number 6, page 1976.
The meeting on April 13, 2021 is being amended to change the time and should read as follows:
Time: 1:00 p.m.3:00 p.m., EDT.
The meeting is closed to the public.
FOR FURTHER INFORMATION CONTACT:
Marilyn Ridenour B.S.N., M.B.A., M.P.H., C.P.H., C.I.C., CAPT, USPHS, Scientific Review Officer, CDC, National Institute for Occupational Safety and Health, 1095 Willowdale Road, Mailstop
Agenda: To review and evaluate grant applications.
Place: National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Room 1078, Bethesda, MD 20892 Virtual Meeting.
Contact Person: Rahat Rani Khan, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Room 1078, Bethesda, MD 20892, 3018947319
khanr2@csr.nih.gov.
Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, BCooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health Prospective Grant of an Exclusive Patent License: Autologous Therapy for the Treatment of Autoimmune Disease Using Chimeric Antigen Receptors Targeting CD19
AGENCY:

National Institutes of Health,
HHS.
ACTION:

Notice.

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Kyverna Therapeutics Kyverna located in Berkeley, CA.

SUMMARY:

E:FRFM18FEN1.SGM

18FEN1